# CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II

> **NCT04516993** · PHASE2 · COMPLETED · sponsor: **Huashan Hospital** · enrollment: 224 (actual)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Tenecteplase
- **DRUG:** The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)

## Key facts

- **NCT ID:** NCT04516993
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-28
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2023-11-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516993, "CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04516993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*